Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From AC Immune SA

Asher Bio Raises $108m For Immune Cell-Specific Therapies

With a CD8-targeting IL-2 mutein as its lead program, the start-up is developing cis-targeted immunotherapies that selectively target two molecules on the same immune cell for improved efficacy and safety.

Financing Innovation

Cautious Optimism As Genentech/AC Immune’s Anti-Tau Antibody Slows Cognitive Decline

Semorinemab met only the cognition co-primary endpoint in the Phase II LAURIET trial in mild-to-moderate Alzheimer’s patients and missed all secondary endpoints, but some firsts were achieved in the top-line readout.

Clinical Trials Neurology

Decentralized Trials Ease Enrollment In Rare Disease Studies

Panel discussion illustrated how decentralized approaches can expand the possibilities of studies in rare diseases, such as cancers with rare genomic alterations.

Clinical Trials Rare Diseases

AC Immune Keeps Faith In Alzheimer’s Breakthrough, But Spreads Risk With Parkinson’s Bet

Interview: The Swiss biotech has endured many Alzheimer’s failures, but has been able to broaden its portfolio and income streams while the search for a breakthrough goes on.

Commercial Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Molecular Diversity
  • Other Names / Subsidiaries
    • AC Immune, Ltd.
UsernamePublicRestriction

Register